Clofazimine as a substitute for rifampicin improves efficacy of Mycobacterium avium pulmonary disease treatment in the hollow-fiber model
Antimicrobial Agents and Chemotherapy · 2024
DOI: 10.1128/aac.01157-23 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2024. Verfasst von Sandra Salillas und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, Pediatrics, Radiology and Public Health, Faculty of Medicine, University of Zaragoza, Zaragoza, Spain. Hauptthemen laut MEDLINE: Mycobacterium avium-intracellulare Infection, Lung Diseases. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Mycobacterium avium complex pulmonary disease is treated with an azithromycin, ethambutol, and rifampicin regimen, with limited efficacy. The role of rifampicin is controversial due to inactivity, adverse effects, and drug interactions. Here, we evaluated the efficacy of clofazimine as a substitute for rifampicin in an intracellular hollow-fiber infection model. THP-1 cells, which are monocytes isolated from peripheral blood from an acute monocytic leukemia patient, were infected with M. avium ATCC 700898 and exposed to a regimen of azithromycin and ethambutol with either rifampicin or clofazimine. Intrapulmonary pharmacokinetic profiles of azithromycin, ethambutol, and rifampicin were simulated. For clofazimine, a steady-state average concentration was targeted. Drug concentrations and bacterial densities were monitored over 21 days. Exposures to azithromycin and ethambutol were 20%–40% lower than targeted but within clinically observed ranges. Clofazimine exposures were 1.7 times higher than targeted. Until day 7, both regimens were able to maintain stasis. Thereafter, regrowth was observed for the rifampicin-containing regimen, while the clofazimine-containing regimen yielded a 2 Log 10 colony forming unit (CFU) per mL decrease in bacterial load. The clofazimine regimen also successfully suppressed the emergence of macrolide tolerance. In summary, substitution of rifampicin with clofazimine in the hollow-fiber model improved the antimycobacterial activity of the regimen. Clofazimine-containing regimens merit investigation in clinical trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Microbiology, Pediatrics, Radiology and Public Health, Faculty of Medicine, University of Zaragoza, Zaragoza, Spain.
- Radboudumc Community for Infectious Diseases, Department of Medical Microbiology, Radboud University Medical Center, Nijmegen, the Netherlands.
- Radboudumc Community for Infectious Diseases, Department of Pharmacy, Radboud University Medical Center, Nijmegen, the Netherlands.
- Department of Pharmacy, Uppsala University, Uppsala, Sweden.
- Radboudumc Community for Infectious Diseases, Department of Pulmonary Diseases, Radboud University Medical Center, Nijmegen, the Netherlands.
ORCID-Profile: Sandra Salillas, Jelmer Raaijmakers, Ralf Stemkens, Jakko van Ingen
Zitieren
APA
Salillas, S., Raaijmakers, J., Aarnoutse, R. E., Svensson, E. M., Asouit, K., van den Hombergh, E., Te Brake, L., Stemkens, R., Wertheim, H. F. L., Hoefsloot, W., & van Ingen, J. (2024). Clofazimine as a substitute for rifampicin improves efficacy of Mycobacterium avium pulmonary disease treatment in the hollow-fiber model. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01157-23
Vancouver
Salillas S, Raaijmakers J, Aarnoutse RE, Svensson EM, Asouit K, van den Hombergh E, et al. Clofazimine as a substitute for rifampicin improves efficacy of Mycobacterium avium pulmonary disease treatment in the hollow-fiber model. Antimicrobial Agents and Chemotherapy. 2024. doi:10.1128/aac.01157-23
BibTeX
@article{Salillas2024,
author = {Salillas, Sandra and Raaijmakers, Jelmer and Aarnoutse, Rob E and Svensson, Elin M and Asouit, Khalid and van den Hombergh, Erik and Te Brake, Lindsey and Stemkens, Ralf and Wertheim, Heiman F L and Hoefsloot, Wouter and van Ingen, Jakko},
title = {Clofazimine as a substitute for rifampicin improves efficacy of Mycobacterium avium pulmonary disease treatment in the hollow-fiber model},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2024},
doi = {10.1128/aac.01157-23}
}
EUVIMED